Trevor Baglin

Trevor is a Venture Advisor at Medicxi. He is Global Head, Hemophilia at Centessa Pharmaceuticals and co-founded Apcintex (acquired by Centessa Pharmaceuticals) and XO1 (acquired by Janssen Pharmaceuticals).

Prior to joining Medicxi he was a clinician at Cambridge University Hospitals where he was also Director of Investigative Sciences. His main research interests were in personalised risk profiling, developed from studying the gene-environment interaction leading to thrombosis, and the molecular basis of blood coagulation, which led to his interest in drug discovery and development. He has published more than 300 clinical and scientific papers and led the production of many national and international guidelines.

Trevor served as President of the British Society for Haematology, President of the British Society for Haemostasis and Thrombosis and was a Founder of the European Congress for Thrombosis and Haemostasis.

He qualified in Medicine from Manchester University, was awarded his PhD from the University of Birmingham and Doctor of Medical Science from Cambridge University.